A large-scale vaccination experiment involving a total of 138 cattle was carried out to evaluate the potential of synthetic peptides as vaccines against foot-and-mouth disease. Four types of peptides representing sequences of foot-and-mouth disease virus (FMDV) C3 Argentina 85 were tested: A, which includes the G-H loop of capsid protein VP1 (site A); AT, in which a T-cell epitope has been added to site A; AC, composed of site A and the carboxy-terminal region of VP1 (site C); and ACT, in which the three previous capsid motifs are colinearly represented. Induction of neutralizing antibodies, lymphoproliferation in response to viral antigens, and protection against challenge with homologous infectious virus were examined. None of the tested peptides, at several doses and vaccination schedules, afforded protection above 40%. Protection showed limited correlation with serum neutralization activity and lymphoproliferation in response to whole virus. In 12 of 29 lesions from vaccinated cattle that were challenged with homologous virus, mutant FMDVs with amino acid substitutions at antigenic site A were identified. This finding suggests the rapid generation and selection of FMDV antigenic variants in vivo. In contrast with previous studies, this large-scale vaccination experiment with an important FMDV host reveals considerable difficulties for vaccines based on synthetic peptides to achieve the required levels of efficacy. Possible modifications of the vaccine formulations to increase protective activity are discussed.
Synthetic peptides are promising candidate vaccines for the control of viral diseases. Early work (2) showed that fragments of the coat protein of tobacco mosaic virus elicited antibodies which recognized the intact virus. Additional studies amply confirmed that synthetic peptides induce antibodies able to interact with the corresponding native proteins or viral particles (3-5, 39, 43, 58, 77) .
Foot-and-mouth disease (FMD) virus (FMDV) is an attractive model with which to study the potential of peptide-based synthetic vaccines (15, 16) . FMD is the economically most important disease of cattle and other farm animals. It is enzootic in many areas of Africa, Asia, South America, and eastern Europe, and its control is based on regular vaccination and slaughter of infected and contact animals (6, 59) . FMD is caused by an aphthovirus of the Picornaviridae family (66) . Seven distinct serotypes, more than 65 subtypes, and many antigenic variants of FMDV have been described (31, 59) . Conventional FMD vaccines consisting of inactivated whole virus have been instrumental in the control of the disease in many areas of the world (9) . However, there are several disadvantages in the use of conventional FMD vaccines: (i) requirement of a cold chain to preserve vaccine stability; (ii) risk of reintroduction of the disease by the handling of infectious virus for vaccine production or by incomplete inactivation of antigen, two problems that were at the origin of several European outbreaks during the last decade (11) ; and (iii) absence of a defined chemical content with regard to both the composition of the viral antigen and the presence of cellular contaminants. The latter have been linked to occasional cases of anaphylactic shock in target animals (9) . In addition, the presence of nonstructural viral proteins in vaccine preparations often makes difficult the distinction between infected and vaccinated animals (62) . Interest in synthetic and subunit anti-FMD vaccines has been apparent since the advent of recombinant DNA technology (41, 42) . Even though initial experiments indicated the potential of bacterially produced capsid protein VP1 to protect swine (41) , it soon became clear that VP1 was several orders of magnitude less immunogenic than the equivalent amount of antigen administered in the form of virus particles (reviewed in references 15, 16, and 31) .
Early immunological studies with FMDV allowed the recognition of two major antigenic sites on capsid protein VP1: site A, located within the G-H loop of VP1 (positions 140 to 160), and site C, located at the carboxy-terminal region of VP1 (1, 12, 72 ; reviewed in references 17 and 46) . Peptide vaccines based on site A or on constructs comprising sites A and C induced significant levels of anti-FMDV neutralizing antibodies and protection in guinea pigs, swine, and cattle (12, 24, 56, 60) . However, their immunogenicity was, in most cases, sub-stantially lower than that of conventional vaccines. There are additional differences between the immune responses induced by peptide vaccines and by classical inactivated FMD vaccines. In animals immunized with inactivated vaccines, a good correlation between neutralizing activity in sera and protection has been observed (73) ; such a correlation has not been well established with animals immunized with synthetic antigens. These limitations probably reflect the difficulties of reproducing the immunogenicity of an entire viral particle by using a much simpler synthetic antigen. An additional problem stems from the antigenic heterogeneity of FMDV in the field (10, 31, 49) , expected from the quasispecies genetic structure of this virus (27) (28) (29) (30) (31) . Current evidence suggests that the simpler the epitopic composition of a synthetic vaccine, the lower the chances of its affording solid protection against natural isolates of viruses (10, 26, 29, 78) . However, previous studies on the immunogenicity of FMD peptides were carried out with limited numbers of animals, and the peptides were designed to contain only VP1 regions characterized as including mainly B-cell epitopes. However, the immune response against FMDV is T cell dependent (reviewed in reference 20) , and therefore synthetic vaccines should incorporate T-cell epitopes to adequately cooperate in the humoral and cell immune responses (22, 34) . In spite of evidence that site A peptides may include also a T-cell epitope recognized by most major histocompatibility complex class II haplotypes of cattle (36) , lymphocytes from peptide-immunized animals did not proliferate in response to the whole virus (74) . This was probably due to an inefficient priming for virus-specific T cells by site A peptides (37, 75) . Recently, a number of FMDV T-cell epitopes, which have become potential candidates to be incorporated into vaccine peptides, have been identified and shown to be recognized by a significant number of individual cattle and pigs (22, 63, 75) . Here we report an investigation on the immune response and protection of cattle afforded by a number of synthetic peptides which include B-and T-cell epitopes corresponding to FMDV C3 Argentina 85 (Arg85). This virus is a representative of serotype C FMDV, a group whose evolution in the field and in cell culture has been previously studied (31, 44, 50) . A large number of cattle were used to provide statistically significant results. We document partial protection (around 30% on average) and the frequent isolation of virus variants with amino acid substitutions at the major antigenic site represented in the peptide vaccines.
MATERIALS AND METHODS
Viruses. Viral stocks derived from FMDV C3 Arg85 (61) were used both for challenge of vaccinated animals and for serological assays. Viruses were amplified in BHK-21 cells, and the average VP1 gene sequence of the viral stocks was determined as described below.
Animals. Hereford steers from an FMDV-free area (Patagonia, Argentina), approximately 12 months old (each weighing 250 to 280 kg), were used for immunization experiments. In all cases, animals were free of previous FMD contact, as confirmed by the absence of detectable anti-FMDV antibodies by serum neutralization (SN) tests.
Peptides and vaccines. Peptides (Table 1) were designed according to the amino acid sequences reported for C3 Arg85 (44, 61) . Peptides were synthesized by solid-phase methods as previously described (18) . Purity was Ͼ95%, as determined by reversed-phase high-performance liquid chromatography; their identities were confirmed by amino acid analysis and electrospray mass spectroscopy. Peptides with amino acid substitutions at positions 24, 140, and 197 of VP1 (designated A*, AT*, AC*, and ACT* in Table 1 ) were also synthesized and used in some vaccination experiments as detailed in the corresponding table footnotes. Substitutions introduced in these peptides correspond to mutations found in the early preparations used to characterize FMDV C3 Arg85 (44, 61) and in different stocks of this virus prepared for the vaccination experiments reported here. The peptides used included (i) the two continuous antigenic sites A and C, previously characterized as including multiple B-cell epitopes in VP1 of type C FMDV (51; review in reference 46); and (ii) a T-cell epitope initially identified in FMDV type O (22) . The amino acid sequence of this T-cell epitope is highly conserved in all type C viruses sequenced (50) , and there is evidence that it may also induce a proliferative response in lymphocytes from animals vaccinated with type C virus (71a). Peptide A includes the B-cell site A of loop G-H of VP1. Peptide AT contains both site A and the T-cell epitope. Peptide AC includes sites A and C; this peptide is the equivalent for FMDV C3 Arg85 of the construct used by DiMarchi et al. (24) for serotype O. Peptide ACT comprises the two B-cell sites colinearly synthesized with the T-cell epitope (Table 1) .
Conventional vaccines included 2 g of binary ethyleneimine-inactivated FMDV C3 Arg85 (8) . The different immunogens were dissolved in phosphatebuffered saline (PBS) and emulsified with an equal volume of oil adjuvant (Arlacel A-Marcol 52 [1:7] -1% Tween 40). A 3-ml volume per dose was administered (65) .
Vaccination and challenge. Animals were kept in isolation throughout the studies. Vaccination was carried out intradermically with the schedules and doses of the different synthetic peptides detailed in the corresponding tables. Animals used as positive controls were vaccinated with a conventional, chemically inactivated vaccine formulated with C3 Arg85 antigen and the oil adjuvant described above. Animals used as negative controls were inoculated with the same volume a Peptides, synthesized as described in Materials and Methods, included FMDV C3 Arg85 amino acid residues (44, 61) corresponding to the following antigenic sites: site A (boldface letters, positions 138 to 156 of VP1); site C (italic letters, positions 196 to 209 of VP1); and T-cell site (underlined, positions 21 to 40 of VP1). Double-underlined letters refer to additional, nonviral amino acids included in the peptides, a terminal cysteine, and a PPS bridge as in the design of DiMarchi et al. (24) .
b Peptides A*, AT*, AC*, and ACT* included the indicated amino acid substitutions present in different preparations of FMDV C3 Arg85 (references 44 and 61 and unpublished observations). To help in VP1 sequence comparisons with other type C FMDV isolates, the fourth residue (the R preceding the conserved RGD motif) in peptide A or A* is assigned position 140a.
of a PBS-oil adjuvant mixture. Vaccinated and control cattle were challenged by tongue intradermal inoculation with 10 4 50% mouse lethal doses of FMDV C3 Arg85 (71) . Animals were periodically inspected for possible occurrence of lesions in the mouth, tongue, lips, buccal mucosa, teats, and feet. Any lesion within 7 days postchallenge was considered rupture of immunity and scored as ϩ in the corresponding tables. Material from vesicles was collected and used for total RNA extraction (19) . To characterize the virus present in the lesions, RNA from vesicles was subjected to reverse transcription (RT)-PCR amplification and sequenced as described below.
Serological analyses. Sera were prepared from blood samples drawn from the jugular vein. SN titers were determined by a plaque reduction test with serial dilutions of each serum and about 200 PFU of C3 Arg85 as previously described (52) . Titers are expressed as the reciprocal of the serum dilution which caused 50% of plaque reduction. The 50% mouse protection dose (MPD 50 ) was determined by subcutaneous inoculation of 0.1 ml of heat-inactivated (30 min, 56ЊC) serum. Two hours later, 50-l aliquots of serial dilutions of C3 Arg85 were administered intramuscularly. The protection index was calculated as reported by Skinner (71) .
An enzyme-linked immunosorbent assay for typing of FMDV-specific bovine immunoglobulin G's (IgGs) in sera from cattle was carried out by using murine monoclonal antibodies (MAbs) 2G6 (anti-IgG1) and 4F10 (anti-IgG2) (kindly provided by C. Stokes and K. Haverson, University of Bristol). Purified FMDV C3 Arg85 (2 g/ml) in PBS was bound to 96-well plates. After saturation with 5% ovalbumin in PBS, threefold dilutions of sera in PBS-2% ovalbumin were added, starting at a 1:50 dilution. Plates were incubated with either a 1:500 dilution of MAb 2G6 or a 1:1,000 dilution of MAb 4F10. Finally, a 1:2,000 dilution of goat anti-mouse IgG-peroxidase was added to the well and developed as described in Rodríguez et al. (63) . Preimmune sera from cattle vaccinated with entire virus and sera from nonimmunized animals were used as negative controls. The A 260 values obtained with these sera never exceeded 0.3 optical density units. Titers were estimated as the log of the last serum dilution that gave an optical density of 0.4. The IgG1/IgG2 ratios were normalized by dividing each value by the average ratio obtained for animals vaccinated with entire virus (this value was 0.98).
Blastogenic assays. Blood samples were collected in the presence of 5 mM EDTA and used to purify peripheral blood mononuclear cells as described by Collen and Doel (21) . About 3 ϫ 10 5 peripheral blood mononuclear cells were incubated in 200 l of RPMI 1640 medium with different concentrations of purified FMDV C3 Arg85. Cells were maintained in culture for 5 days, and incorporation of radioactivity into cellular DNA was measured after 6 h of incubation with 1 Ci of [ (67) . Results, corresponding to the highest proliferation values scored for each animal, are expressed as the stimulation index (SI) (cpm in sample/cpm with culture medium alone). The response was considered positive when the SI was Ն3.
VP1 RNA sequencing. RNA obtained from vesicles or extracted with phenol directly from viral stocks was used for the amplification of VP1 sequences. RNA was copied into cDNA and amplified by using Taq polymerase (RT-PCR). The following oligonucleotides were used to prime the cDNA extension (sequences are given in 5Ј-3Ј polarity, and numbering corresponds to the C3 Arg85 sequence [61] ): oligonucleotide pR5, GGAGGGCCCAGGGTTGGACT (complementary to positions 34 to 35 of the 2AB genes); and oligonucleotide 2ϩFIN, GCCAA CATAGCCCCGACCAACG (spanning positions 856 to 877 of P1). Direct sequencing of the PCR products was performed by using an fmol sequencing kit (Promega) as described previously (68) 
RESULTS
Immune response of cattle to synthetic peptides. The aim of this study was to assess the immune response and protection induced by peptidic vaccines which contained VP1 sequences including B-and T-cell epitopes of capsid protein VP1 (Table  1) . We first analyzed the ability of synthetic peptides A, AT, AC, and ACT to elicit a humoral and cellular immune response in cattle. Groups of three to four animals per peptide were vaccinated with 1 mg and boosted with 0.1 mg of peptide A or with the molar equivalent in the case of peptides AT, AC, and ACT (high dose). Other groups of three to four animals per peptide were vaccinated and boosted with 0.1 mg of peptide A or the molar equivalent of peptides AT, AC, and ACT (low dose). The results (Table 2) showed considerable animalto-animal variation in SN titers at 26 and 46 days postimmunization (dpi) (before and after the booster immunization, respectively). Despite this, a trend toward an increase of the SN titers after boosting was observed. The average SN titers at 46 dpi corresponding to animals vaccinated with ACT (2.2 Ϯ 0.5), AC (2.0 Ϯ 0.6), and AT (1.7 Ϯ 0.5) were higher than those obtained for animals vaccinated with A (1.0 Ϯ 0.5).
Comparison of the blastogenic responses (SIs [ Table 2 ]) indicates that lymphocytes from most animals immunized with peptide A or AC did not proliferate in response to complete virus, while lymphocytes from three of the six cattle immunized with peptide A and from two of six cattle immunized with peptide AC proliferated in response to the corresponding peptide (Table 2) . However, lymphocytes from three of five animals immunized with AT and two of six immunized with ACT gave significant SIs in response to the whole virus, a result consistent with the recognition by these animals of T-cell epitopes present in the FMDV particles. In addition, lymphocytes from all the animals immunized with peptide AT or ACT proliferated in response to the synthetic peptide used for immunization.
Animals vaccinated with the inactivated virus exhibited high SN titers at 26 dpi as well as significant SIs in response either to whole virus or to most of the peptides, while, as expected, no significant titers were obtained for the control, nonimmunized animals ( Table 2) .
Effects of different schedules of immunization and challenge in the response of cattle to synthetic peptides. To investigate the effects of modifications in the timing of the immunization with synthetic peptides in the response, two groups of three to six animals per peptide dose were immunized with the high or low doses of the four peptides, as in the experiment described in Table 2 . In this second experiment, SN titers were determined at 35 and 69 dpi, and SIs were measured with lymphocytes extracted at 69 dpi. The results confirmed a general animal-to-animal variation in the overall response observed (Table 3) . Similar SN titers and SIs were observed among animals immunized with the different peptide antigens. Protection reached 50% (three of six animals protected) for peptide A, 33% (three of nine) for AT, and 25% (two of eight) for peptides AC and ACT. Lymphocytes from each of the protected animals proliferated significantly in response to whole virus. However, some responder animals were not protected. In general, no significant differences were observed among animals vaccinated with high or low doses of peptides.
A third experiment was designed with a selected peptide (peptide A*) to further investigate the influence of the immunization schedule on the response induced. Groups of six animals were immunized and challenged by using either the schedule of the experiment described in Table 3 (booster at 35 dpi and challenge at 69 dpi) or a booster at 69 dpi and challenge at 138 dpi. The results (Table 4) showed again considerable animal-to-animal variation in the response to peptide A*. No significant differences between the two immunization schedules used were noticed. Average SN titers among the animals boosted at 35 dpi were 2.2 Ϯ 0.7, and only one of six animals was protected, while two of six animals boosted at 96 dpi (average SN titers of 2.3 Ϯ 0.8) were protected. A limited correlation was observed between the ability of the sera to protect suckling mice infection (MPD 50 titers) and resistance to challenge (Table 4) .
Evaluation of the protection of cattle conferred by synthetic peptides A, AT, and ACT. To further evaluate the possible correlation between the immune response induced by the selected peptides and protection, we performed an additional experiment in which 2 mg of peptide A, or the molar equivalents of peptides AT and ACT, was used for both the first vaccination and the booster immunization at day 26 postimmunization (p.i.). Groups of 15 or 16 animals were immunized with each of the peptides and were challenged at day 46 p.i. (Table 5 ). In general, the SN values determined at 46 dpi were consistent with those found in previous experiments, and increases in titer were observed after boosting. Animals vaccinated with peptide A showed, on average, lower SN titers (1.7 Ϯ 0.5) and higher individual variation than those in the groups vaccinated with either AT (2.4 Ϯ 0.3) or ACT (2.4 Ϯ 0.3). The percentage of animals protected never exceeded 50%; values were 12.5% (2 of 16) with peptide A, 25% (4 of 16) with AT, and 46% (7 of 15) with ACT. All protected animals showed SN titers higher than 2, but not all animals with high SN titers were protected. Again, a limited correlation between high MPD 50 titers and protection was observed in cattle immunized with peptides A and AT. This correlation was higher for cattle immunized with peptide ACT, in that all protected animals exhibited MPD 50 titers of Ͼ2.8. An analysis of the FMDV-specific IgGs present in animals vaccinated with peptide A revealed that the relative IgG1/IgG2 ratios observed were, on average, significantly higher (values above 1 in Table  5 ) than those obtained for virus-vaccinated cattle. This difference was lower for animals vaccinated with peptide AT or ACT.
Analysis of FMDV recovered from unprotected animals. A sequence analysis of the virus present in the lesions developed by some animals vaccinated with peptide A, AT, or ACT was carried out by RT-PCR of RNAs directly extracted from lesions, without adaptation of the virus to cell culture. The average nucleotide sequences spanning antigenic site A included a Peptides A, AT, AC, and ACT are described in Table 1 . Except as noted in footnote b, 1 and 0.1 mg of peptide A, or the molar equivalents for peptides AT, AC, and ACT, were used for the first immunization and the booster, respectively.
b One-tenth milligram of peptide A, or the molar equivalent for longer peptides, was used for both the first immunization and the booster. c Log of the serum dilution causing a 50% reduction in the number of PFU as previously described (52) . Each value is the average of at least two determinations. Blank spaces indicate assays not done.
d Neg, lymphoproliferation was not significant. Blank spaces indicate assays not done.
in the peptides revealed the presence of variants with a unique amino acid substitution in 12 of 29 samples tested (Table 6 ). Substitution R(141)3G at the RGD motif was found in two lesions from animal L9; substitution L(144)3P was found in six lesions from animals 7, L12, and 40; and substitution L(147)3P was found in four lesions from animals 25, 40 and L5. These residues have been shown to be critically involved in site A antigenicity (46, 76) (see Discussion). Thus, in 41% of the lesions analyzed, variant viruses with antigenically critical substitutions in site A were detected.
DISCUSSION
Early work with FMDV identified VP1 fragments able to elicit a potent antibody response against the intact virus (7, 40) . In spite of promising results with respect to immunization of guinea pigs, mice, and cattle with various synthetic peptides (12, 24, 34, 60) , no synthetic vaccines against FMDV have been commercialized, nor are they, to our knowledge, being tested in experimental trials in the field, even in areas where FMD is enzootic. In this study, the use of a large number of animals provided statistically significant evidence for a lack of solid protection in bovines vaccinated with peptides representing FMDV C3 Arg85 VP1 sequences (Table 7) . Thus, in spite of evidence of some homotypic and heterotypic protection by synthetic peptides in guinea pigs and cattle (25) , a firm and consistent protection in bovines is not systematically achieved (35) . An inactivated vaccine acceptable for use in the field must attain 80% protection in cattle (9); 90% protection was obtained with the whole-virus vaccine used as a positive vaccination control in our experiments (Tables 3 to 5) . With the synthetic peptides tested, protection was always lower than 50%, with a global maximum of 39% protection obtained with the more complex peptide ACT (Table 7) . Challenge was by tongue intradermal inoculation with homologous infectious virus, as required for official testing of anti-FMDV vaccines. It cannot be excluded that a different level of protection may be obtained if the animals are challenged in a different way (aerosol spreading with viral suspensions, contact with infected animals, etc.). No consistent correlations could be established between individual protection with each of the different peptides and the immunological parameters studied. In general, e ϩ, protected animal; Ϫ, nonprotected animal with at least one lesion in any of the four feet. sera from most of the protected animals showed high SN and MPD 50 titers, and their lymphocytes were able to proliferate in response to the virus. However, a fraction of the animals that exhibited similar characteristics were not protected. A difference in ratio between the titers of IgG1 and IgG2 classes of immunoglobulins has been proposed as the reason for the poor correlation between antibody levels and protection (57). Our results indicate that animals vaccinated with peptides show higher relative IgG1/IgG2 ratios than animals vaccinated with inactivated virus. This difference is more prominent in the case of vaccination with peptide A, and it is mostly due to a decrease in the IgG2 titer. Altogether, these results suggest that mechanisms other than the direct neutralization of viral particles by anti-FMDV antibodies may play a role in protection (54) .
Part of the low efficacy of synthetic antigens may originate in the wide animal-to-animal variations in response, as revealed by the parameters analyzed in our study. Individual variation has been reported in swine vaccinated with inactivated virus, with antigenic site A of FMDV C-S8 being immunodominant in some animals and immunosilent in others (48) . Animal-toanimal variations are expected to be more accentuated as fewer B-and T-cell epitopes are included in a vaccine. This is because polymorphisms in genes of class I and class II major histocompatibility complexes may affect recognition of individual epitopes, thus resulting in variations in both cellular and antibody responses among individual animals. These types of variations are buffered as a result of a wider repertoire of antigenic stimuli such as those present in whole-virus vaccines (10, 29, 70) .
Consistently with the requirement of an adequate B cell-T cell interaction, lymphocytes from most of the animals protected significantly proliferated in response to the whole virus (Tables 3 and 5 ). This finding suggests that not only peptides AT and ACT but also peptide A contain T-helper epitopes which induce virus-specific T cells in a fraction of the animals immunized (33) . The presence of such T-cell epitopes was not sufficient to afford consistent protection, and a more adequate vaccine formulation may be required to reach the protection frequencies of current whole virus vaccines.
On occasions, the colinear expression of T-helper epitopes with B-cell epitopes in peptide vaccines has resulted in enhanced antibody responses (13, 22) . However, the design of adequate combinations of T-cell and B-cell epitopes in peptide vaccines so as to retain their functionality remains a complex and often unpredictable exercise (23, 38, 69) .
In addition to the problems derived from limited representation of epitopes in peptide vaccines, a body of evidence indicating extreme genetic heterogeneity (quasispecies structure) of RNA viruses, including FMDV, has accumulated in recent years (10, 26-31, 49-53, 55, 64, 68, 78) . In animals vaccinated with synthetic peptides and then challenged with infectious virus, 12 of 29 lesions analyzed (corresponding to 6 of the 13 animals studied) contained viruses with amino acid replacements within antigenic site A (Table 6) , as judged by sequence analysis of material from the lesions, without adaptation of virus to cell culture. One replacement affected the RGD triplet involved in cell recognition (32, 45) . However, the sequence changed from RRGD to RGGD. Thus, an R(X)GD motif was preserved. The same variant sequence has been detected in the field isolate FMDV C2 Pando Ur 44 (44) . It is also remarkable that VP1 position 144 found substituted in viruses from six lesions is equivalent to a heterogeneous position identified among plaque isolates of an FMDV A12 preparation (64) . Also, a substitution at position 144 occurred upon growth of a C1 field virus in cell culture (55) . Analyses with monoclonal and swine polyclonal antibodies directed to antigenic site A showed that substitutions at positions 141, 144, and 147 found in the lesions of diseased animals drastically affect antibody recognition of this antigenic site (47, 53, 53a, 76) . Additional studies and implications of the substitutions identified in the escape variants of FMDV C3 Arg85 will be presented elsewhere. Recently, the emergence of escape mutants of lymphocytic choriomeningitis virus in mice vaccinated with peptides consisting of T-cell epitopes was reported (78), a For those animals in which samples from more than one lesion were available, the VP1 sequences corresponding to two or more independent lesions are shown. Sequences are shown in Table 1 , assigning position 140a to the R residue preceding the RGD motif (see footnote b of Table 1 ). a The compositions of the different peptides, including amino acid residues of capsid protein VP1 from FMDV C3 Arg85, are detailed in Materials and Methods and in Table 1 .
b Total number of animals immunized with each of the synthetic peptides that were challenged with FMDV C3 Arg85 (Tables 3 to 5) .
c Average protection observed in the challenge assays with FMDV C3 Arg85 (see Materials and Methods for details) among animals immunized with each of the synthetic peptides in different experiments (Tables 3 to 5). again evidencing the limitations of simple, peptide vaccines to achieve protection against highly variable RNA viruses. In the case of FMDV, since deviant antigenic forms of antigenic site A were as immunodominant as the parental sequences (14) , a possible increase in the efficacy of peptide vaccines may be attained by enlarging the repertoire of independent B-cell and T-cell epitopes, together with variant forms of some of them. This may expand the overall response as well as the ability to protect against mutants that may potentially arise in the course of viral replication. Such attempts are now in progress.
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